Latest Breaking News On - Maat pharma - Page 5 : comparemela.com

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

LYON, France, March 12, 2024 Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients. The data will be shared during an oral p

United statesGlasgow cityUnited kingdomAlexander schauwvliegheMichael loschiEarly access programCorporate communicationsAmerican society of hematologyMeeting of the european society for bloodTrophic communicationsSenior pr corporate communicationsGraft vs host diseaseMaat pharmaRegulatory newsMicrobiome ecosystemOverall survival

MaaT Pharma : Inside Information / Other news releases -March 12, 2024 at 04:46 am EDT

Press release MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference .

Alexander schauwvliegheSenior pr corporate communicationsTrophic communicationsEarly access program in europeOral presentationRefractory gastrointestinalEarly access programMaat pharmaMicrobiome ecosystem therapiesEuronext parisInvestor relations

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Lou gehrigSenior pr corporate communicationsEuropean medicines agencyTrophic communicationsIndependent data safetyMonitoring boardMicrobiome ecosystemAmyotrophic lateral sclerosisOrphan drug designationMaat pharmaMicrobiome ecosystem therapiesEuronext parisInvestor relationsCommunications manager

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Lou gehrigEuropean medicines agencyMicrobiome ecosystemOrphan drug designationMaat pharmaMicrobiome ecosystem therapiesEuronext parisMaat pharma stock

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Guilhaume debroasStefan klotterPauline richaudTrophic communicationsRegulations of the financial markets authorityCorporate communicationsGeneral regulationsFinancial markets authorityDes marchMicrobiome ecosystemFrench commercial codeFrench autoritEuronext parisMaat pharmaMicrobiome ecosystem therapiesInvestor relations